- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00186797
Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia (AACD34)
This study is for patients with Severe Aplastic Anemia (SAA). A stem cell transplant from a genetically matched sibling donor can help or cure this disease in 85 to 100 percent of patients. Stem cells are immature blood cells that grow to become red blood cells, white blood cells or platelets. A genetic "match" means a brother or sister has same immune type (HLA type) as the patient. Unfortunately, few patients have a matched sibling donor. The chance of negative outcomes is much higher with other types of donors.
This study will test the success of a new approach to stem cell transplant for SAA. Patients in this study will receive drugs and radiation treatment to destroy their diseased bone marrow and to prepare them for stem cell transplant. Bone marrow is the tissue inside the bones where stem cells are made.Stem cells will be harvested from the blood or bone marrow of genetically matched unrelated donors or partially matched family donors. The stem cells will be filtered using a new device that is currently under study. The patients will receive large doses of the filtered stem cells (stem cell graft). Researchers want to find out how the study treatment affects patients, the disease, and the chances for survival.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age < 21 years
- Diagnosis of severe aplastic anemia. (As defined by at least 2 of the following: ANC < 500/μl, platelet count < 20,000/μl, and a reticulocyte count < 1% after correction for the hematocrit. In addition, the diagnostic bone marrow biopsy must contain less than 25% of the normal cellularity).
- Patient must have failed one or more courses of immunosuppressive therapy that included ATG. As immunosuppression may take up to 6 months to demonstrate a response, patients must have been observed to have failed immunosuppression for a minimum of six months.
- Absence of suitable HLA-matched sibling donor.
- Negative serum pregnancy test for females with child bearing potential.
- Patient/parent/guardian is able to provide informed consent.
Exclusion Criteria:
- Patients with a life expectancy < 6 weeks.
- Patients with severe renal disease (creatinine clearance < 40cc/min/1.73m2)
- Patients with pre-existing severe restrictive pulmonary disease (FVC <40% of predicted)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To learn the safety of stem cell transplantation in patients with unrelated donors or partially matched family donors
|
To study the effects (good and bad) of this treatment on the patients, the aplastic anemia, and survival
|
To learn how well the donor bone marrow grows in patients who receive the research treatment
|
To learn how many patients need extra T-cells or extra stem cells from the donor to help the donor's blood stem cells grow
|
Collaborators and Investigators
Investigators
- Principal Investigator: Paul Woodard, MD, St. Jude Children's Research Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Bone Marrow Diseases
- Hematologic Diseases
- Bone Marrow Failure Disorders
- Anemia
- Anemia, Aplastic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Fludarabine
Other Study ID Numbers
- AACD34
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aplastic Anemia
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
University of UtahNovartisCompletedSevere Aplastic Anemia | Moderate Aplastic Anemia | Very Severe Aplastic AnemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Severe Aplastic Anemia | Refractory Severe Aplastic AnemiaUnited States
-
Peking University People's HospitalRecruiting
-
Boston Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsRecruitingSevere Aplastic AnemiaUnited States
-
Federal Research Institute of Pediatric Hematology...RecruitingAcquired Aplastic AnemiaRussian Federation
-
Shanghai General Hospital, Shanghai Jiao Tong University...Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine and other collaboratorsCompleted
-
Nagoya UniversityUnknownAcquired Aplastic Anemia.Japan
-
Navy General Hospital, BeijingPeking Union Medical College Hospital; Cancer Institute and Hospital, Chinese... and other collaboratorsUnknownSevere Aplastic AnemiaChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
Clinical Trials on Allogeneic stem cell transplant
-
National Cancer Institute (NCI)TerminatedAcute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Hodgkins LymphomaUnited States
-
Center for International Blood and Marrow Transplant...National Marrow Donor ProgramRecruitingMultiple MyelomaUnited States
-
St. Jude Children's Research HospitalCompletedAnemia, Aplastic | Diamond-Blackfan Anemia | Amegakaryocytic Thrombocytopenia | Kostmann SyndromeUnited States
-
Tata Memorial CentreNot yet recruiting
-
Children's Hospital Medical Center, CincinnatiTerminatedAllogeneic Hematopoietic Cell TransplantationUnited States
-
St. Jude Children's Research HospitalCompletedAcute Myeloid Leukemia | Leukemia | Hodgkin's Lymphoma | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Paroxysmal Nocturnal HemoglobinuriaUnited States
-
David Rizzieri, MDCompletedLeukemia | Myelodysplasia | Myeloma | Non Hodgkin's Lymphoma | Hodgkin's DiseaseUnited States
-
Porteus, Matthew, MDCalifornia Institute for Regenerative Medicine (CIRM)RecruitingHematologic DiseasesUnited States
-
M.D. Anderson Cancer CenterZiopharm OncologyCompletedLymphoma | LeukemiaUnited States
-
St. Jude Children's Research HospitalCompletedJuvenile Myelomonocytic Leukemia | Non-Hodgkin Lymphoma | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Acute Lymphoblastic Leukemias | Acute Myelocytic Leukemia | Hemoglobinuria, ParoxysmalUnited States